Diadema Partners »

Taysha Gene Therapies shares owned by Diadema Partners

Quarter-by-quarter ownership of Taysha Gene Therapies (TSHA) shares owned by Diadema Partners from 13F filings

Historical chart of Diadema Partners investment in Taysha Gene Therapies

Tip: Access up to 7 years of quarterly data

All positions including Taysha Gene Therapies held by Diadema Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Taysha Gene Therapies by Diadema Partners

Quarter filed Position value Share count Share price at filing
2026-06-30 $3.6M 523k 6.81

More positions owned by Diadema Partners

Abivax Sa Sponsored Ads Call Option (ABVX)
Viking Therapeutics (VKTX)
Bristol Myers Squibb Put Option (BMY)
Amgen Call Option (AMGN)
United Therapeutics Corporation (UTHR)
Revolution Medicines (RVMD)
Uniqure Nv SHS Put Option (QURE)
Novartis Sponsored Adr Call Option (NVS)
Kodiak Sciences Call Option (KOD)
Capricor Therapeutics Com New Put Option (CAPR)
Cogent Biosciences (COGT)
Bridgebio Pharma Note 1.750% 3/0 (Principal)
Corcept Therapeutics Incorporated Call Option (CORT)
BioMarin Pharmaceutical (BMRN)
Kymera Therapeutics Call Option (KYMR)

View all positions for Diadema Partners

Top funds holding Taysha Gene Therapies

venBio Select Advisor
RA Capital Management
Goldman Sachs Group
BlackRock
Vestal Point Capital
Morgan Stanley
Rtw Investments
FMR
Vanguard Capital Management
State Street Corporation
Siren
Octagon Capital Advisors
Geode Capital Management
Polar Capital Holdings
MPM Oncology Impact Management

View all funds holding Taysha Gene Therapies